In what may be a breakthrough for India in vaccine production and development of monoclonal antibodies (MABS) against the Nipah virus, the Institute of Advanced Virology (IAV) in Kerala has developed non-infectious Nipah virus-like particles (VLPs).
This will also help in testing the effectiveness of preventing the entry of Nipah in target cells. This is a major development as India used to import antibodies.
During the 2018 outbreak, a non-patented drug developed by Christopher C Broder from Australia was imported for compassionate use from the University of Queensland.
Last year, Business Standard had reported that the Indian Council of Medical Research (ICMR) is in talks with the Serum Institute of India (SII) for local manufacturing of MABS. The MABS are used on compassionate grounds for treating Nipah virus infections. However, it did not take off, as the volume was much less in India.
This story is from the June 04, 2024 edition of Business Standard.
Start your 7-day Magzter GOLD free trial to access thousands of curated premium stories, and 9,000+ magazines and newspapers.
Already a subscriber ? Sign In
This story is from the June 04, 2024 edition of Business Standard.
Start your 7-day Magzter GOLD free trial to access thousands of curated premium stories, and 9,000+ magazines and newspapers.
Already a subscriber? Sign In
Women in a shadow war
In the 21st century, many countries have started admitting women into the military in combat roles as fighter pilots and frontline soldiers in grudging recognition of their capabilities and courage.
NCPA-Soho 1st theatrical tie-up blurs boundaries
Indian 'drag kings' to take stage in Mumbai, London in Gentlemen's Club
GAINS AT PUMPS SUPERNORMAL
But low cracks, or profits from processing crude oil into petrol & diesel, have contributed to abysmal refining margins, prompting rethink on lowering retail fuel prices
Everybody wants a 'piece' on Dwarka Expressway
Dwarka Expressway, a 29.1-kilometre (km)-long 16-lane stretch between Shiv Murti in Delhi and Kherki Daula in Gurugram, has become a real estate hotspot, attracting top developers from all over the country announcing their projects in the area.
Accumulate gold through SIP if portfolio allocation below 10%
Gold, which closed at ₹75,447 per 10 gram in the domestic market on Friday (and is trading at ₹2,689.6 per ounce on the Comex), is up 29.4 per cent over the past year.
IT aims for sky after Accenture's Q4 results
Nifty IT index ends 0.4% higher over previous close
NSE, BSE revise transaction fee
Stock exchanges National Stock Exchange (NSE) and BSE on Friday revised their charges for various segments in the market — to align them with the true-to-label circular by the Securities and Exchange Board of India (Sebi) which mandates uniform fee irrespective of the turnover.
GQG Partners settles charges with US SEC
Boutique investment firm GQG Partners has settled charges of potential violations of whistleblower rules with the Securities and Exchange Commission (SEC) — the regulatory body in the United States — by paying a $500,000 penalty.
Sebi plans mandatory disclosures for direct plan MF schemes
The Securities and Exchange Board of India (Sebi) has proposed to make it mandatory for mutual fund houses to give separate disclosures for direct plan and regular plan schemes in their half-yearly financial results.
Crompton Greaves Consumer may underperform on demand concerns
The stock of Crompton Greaves Consumer Electricals has shed about 12 per cent since the start of the month due to a muted near-term outlook.